Our findings have direct implications in cancer immunotherapy where NKG2D-based strategies are the focus of intense research64, 65, 66, 67, 68 and a phase I trial for NKG2D CAR T-cell therapy is currently recruiting patients. The gene discussed is KLRK1; the disease is cancer.